Who benefits if NHS drug prices soar? Donald Trump and big pharma. Just one more way he’s menacing Britain | Polly Toynbee
The article discusses the potential impact of Donald Trump's threats on the UK's pharmaceutical industry and the National Health Service (NHS). It highlights how Trump's proposal to impose a 250% tariff on medicines made abroad by pharmaceutical companies, unless they move their operations to the US, is already driving out major drugmakers from the UK. This includes AstraZeneca's decision to scrap a £450m vaccine plant in Liverpool and Merck's cancellation of a £1bn research facility in London. The article argues that this poses a serious threat to the NHS's ability to access affordable drugs, as well as the UK's thriving life sciences sector. The author, Polly Toynbee, criticizes the UK government's "grovelling" to Trump and suggests that this is just one more way the US president is "menacing Britain."
Source: For the complete article, please visit the original source link below.
